BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 15179002)

  • 1. Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia.
    Müller MC; Hördt T; Paschka P; Merx K; La Rosée P; Hehlmann R; Hochhaus A
    Acta Haematol; 2004; 112(1-2):30-3. PubMed ID: 15179002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization.
    Müller MC; Merx K; Weisser A; Kreil S; Lahaye T; Hehlmann R; Hochhaus A
    Leukemia; 2002 Dec; 16(12):2395-9. PubMed ID: 12454744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
    Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
    Kim YJ; Kim DW; Lee S; Min CK; Goh HG; Kim SH; Lee JY; Kim YL; Kim HJ; Kim HJ; Lee JW; Kim TG; Min WS; Kim CC
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):718-25. PubMed ID: 15389438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of RNA stabilization on minimal residual disease assessment in chronic myeloid leukemia.
    Thörn I; Olsson-Strömberg U; Ohlsen C; Jonsson AM; Klangby U; Simonsson B; Barbany G
    Haematologica; 2005 Nov; 90(11):1471-6. PubMed ID: 16266893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA.
    Bartley PA; Ross DM; Latham S; Martin-Harris MH; Budgen B; Wilczek V; Branford S; Hughes TP; Morley AA
    Int J Lab Hematol; 2010 Dec; 32(6 Pt 1):e222-8. PubMed ID: 20491997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid quantitative detection of BCR-ABL transcripts in chronic myeloid leukemia patients by real-time reverse transcriptase polymerase-chain reaction using fluorescently labeled probes.
    Bolufer P; Sanz GF; Barragán E; Sanz MA; Cervera J; Lerma E; Senent L; Moreno I; Planelles MD
    Haematologica; 2000 Dec; 85(12):1248-54. PubMed ID: 11114130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples.
    Stock W; Yu D; Karrison T; Sher D; Stone RM; Larson RA; Bloomfield CD
    Int J Oncol; 2006 May; 28(5):1099-103. PubMed ID: 16596225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia.
    Lundán T; Juvonen V; Mueller MC; Mustjoki S; Lakkala T; Kairisto V; Hochhaus A; Knuutila S; Porkka K
    Haematologica; 2008 Feb; 93(2):178-85. PubMed ID: 18223279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-time quantitative reverse transcriptase polymerase chain reaction.
    Fan H; Robetorye RS
    Methods Mol Biol; 2010; 630():199-213. PubMed ID: 20300999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation.
    Uzunel M; Ringdén O
    Bone Marrow Transplant; 2004 Jan; 33(1):47-52. PubMed ID: 14704656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of a new RNA stabilizing reagent (Tempus Blood RNA) for minimal residual disease in onco-hematology using the EAC protocol.
    Prezeau N; Silvy M; Gabert J; Picard C
    Leuk Res; 2006 May; 30(5):569-74. PubMed ID: 16209886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standardisation of molecular monitoring for chronic myeloid leukaemia.
    Cross NC
    Best Pract Res Clin Haematol; 2009 Sep; 22(3):355-65. PubMed ID: 19959086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Standardization of quantitative detection of BCR-ABL gene expression by RQ-PCR in patients with chronic myeloid leukemia in cooperation with European Leukemia Net].
    Sacha T; Zawada M; Czekalska S; Florek I; Mueller M; Gniot M; Jaźwiec B; Kyrcz-Krzemień S; Leszczyńska A; Lewandowski K; Matiakowska K; Solarska I; Stokłosa T; Skotnicki AB
    Przegl Lek; 2010; 67(7):454-9. PubMed ID: 21387754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The monitoring of residual disease for chronic myelogenous leukemia patients treated with imatinib mesylate: detection of T315I mutation in ATP binding site of BCR/ABL gene].
    Miyanishi S; Umeki K; Hayashi T; Fukutsuka K; Okumura A; Kishimori C
    Rinsho Byori; 2003 Oct; 51(10):1023-9. PubMed ID: 14653203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].
    Xing W; Gu BW; Zhu YM; Jiang CL; Zhao RH; Wang AH; Sun HP; Li JM; Shen ZX; Chen Z; Chen SJ
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):453-7. PubMed ID: 15854550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Using real-time polymerase chain reaction to quantitate bcr-abl mRNA].
    Liu JX; Liu JL; Wang GJ
    Ai Zheng; 2006 Nov; 25(11):1447-9. PubMed ID: 17094919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay.
    Goh HG; Lin M; Fukushima T; Saglio G; Kim D; Choi SY; Kim SH; Lee J; Lee YS; Oh SM; Kim DW
    Leuk Lymphoma; 2011 May; 52(5):896-904. PubMed ID: 21338281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.
    Gabert J; Beillard E; van der Velden VH; Bi W; Grimwade D; Pallisgaard N; Barbany G; Cazzaniga G; Cayuela JM; Cavé H; Pane F; Aerts JL; De Micheli D; Thirion X; Pradel V; González M; Viehmann S; Malec M; Saglio G; van Dongen JJ
    Leukemia; 2003 Dec; 17(12):2318-57. PubMed ID: 14562125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
    Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
    Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.